SCHEMBL7182706

SCHEMBL7182706

O=C(Pc1ccccc1)c1c(Cl)cc(Cl)cc1Cl.[LiH]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 8/20 0.40
TSHR P16473 1/20 0.37
CASP1 P29466 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTPRC P08575 1/20 0.37
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
AKR1C4 P17516 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
CHRM1 P11229 1/20 0.36
ALDH1A1 P00352 1/20 0.35
RORC P51449 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
CES2 O00748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7179685 0.85 ALDH1A1 (0.48) TSHRMAPTNPSR1MEN1KMT2A
SCHEMBL7190264 0.84 ALDH1A1 (0.34) TSHRCASP1MAPTNPSR1MEN1
SCHEMBL7174576 0.82 ALDH1A1 (0.50) TSHRMAPTNPSR1MEN1KMT2A
SCHEMBL7175625 0.81 DPP4 (0.38) TSHRMAPTMEN1KMT2AALDH1A1
SCHEMBL7190182 0.81 ALDH1A1 (0.33) TSHRMEN1KMT2AALDH1A1CES2
SCHEMBL7183974 0.77 ALDH1A1 (0.46) TSHRMEN1KMT2AALDH1A1LMNA
SCHEMBL7175177 0.76 FABP3 (0.46) MAPTKMT2AALDH1A1RORCLMNA
SCHEMBL7182551 0.75 LMNA (0.45) TSHRSMN1; SMN2MAPTMEN1RAB9A
SCHEMBL7180878 0.75 PTGS2 (0.40) TSHRMAPTMEN1KMT2AAKR1C3
SCHEMBL7188950 0.74 ALDH1A1 (0.58) TSHRSMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SPR 2111/4885TSHR 984/4885CASP1 3392/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SPR 1676/4885TSHR 1273/4885CASP1 3681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.